AZN logo

AstraZeneca PLC

AZN
Healthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23

About

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Stock Price

+10.3%(1Y)
1M
+17.4%
3M
+15.5%
6M
+2.0%
YTD
+6.2%
1Y
+6.6%
3Y
+49.0%
5Y
+45.2%

Pipeline Summary

507 total trials
123
Phase 1
126
Phase 2
114
Phase 3
37
Phase 4
Recruiting: 49Terminated: 36Completed: 355Active: 36By Invitation: 1Unknown: 10Withdrawn: 12Suspended: 2Not Yet Recruiting: 5Approved: 1

Active Trials (85)

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis
Recruiting
Enrollment: 1,850 participants
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
Recruiting
Enrollment: 4,000 participants
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
Phase 3Recruiting
Enrollment: 150 participants
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
NCT06981169Asthma
Recruiting
Enrollment: 1,500 participants
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
Phase 3Recruiting
Enrollment: 245 participants

BioScore

5.9/10
Watchlist

Key Facts

Market Cap$289.13B
Employees96,100
CEOPascal Claude Roland Soriot
IPO DateMay 12, 1993
Beta0.21
52-Week Range$153.41 – $212.71
Avg Volume3,346,054
ExchangeNYSE

Ownership

Float99.5%
Shares Outstanding1550.9M

Recent Insider Trades

Sharma ManiAWARD
Oct 6, 20262 shares @ $159.80
Sharma ManiAWARD
Sep 8, 20261 shares @ $162.60
Sharma ManiBUY
Aug 8, 202620.233 shares @ $160.57
Sharma ManiAWARD
Aug 6, 20262 shares @ $163.34
Sharma ManiAWARD
Jul 6, 20262 shares @ $190.43

Peers

ABBVAbbVie Inc.
$514.78B
AMGNAmgen Inc.
$248.92B
BMYBristol-Myers Squibb Company
$127.02B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
MRKMerck & Co., Inc.
$361.96B
NVONovo Nordisk A/S
$177.74B
NVSNovartis AG
$307.00B
Data last updated: Nov 9, 2026, 03:57 AM